Bruker (NASDAQ:BRKR) Price Target Cut to $50.00 by Analysts at Guggenheim

Bruker (NASDAQ:BRKR) had its price objective dropped by investment analysts at Guggenheim from $58.00 to $50.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Guggenheim’s price objective indicates a potential upside of 44.74% from the stock’s current price.

Other research analysts have also issued research reports about the company. Jefferies Financial Group set a $50.00 target price on Bruker in a report on Thursday, February 12th. TD Cowen lowered their price target on shares of Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a report on Friday, February 13th. Wolfe Research raised shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective for the company in a research note on Wednesday, December 10th. JPMorgan Chase & Co. upped their target price on shares of Bruker from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Finally, UBS Group reiterated a “neutral” rating and issued a $49.00 target price on shares of Bruker in a research note on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Bruker presently has a consensus rating of “Hold” and an average price target of $49.77.

Bruker Stock Performance

BRKR stock traded up $0.83 during midday trading on Monday, reaching $34.55. 551,864 shares of the company’s stock traded hands, compared to its average volume of 2,434,308. The firm has a market capitalization of $5.26 billion, a PE ratio of -230.28, a price-to-earnings-growth ratio of 2.02 and a beta of 1.19. The company has a 50-day moving average price of $40.06 and a two-hundred day moving average price of $41.29. Bruker has a 52 week low of $28.53 and a 52 week high of $56.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The company had revenue of $977.20 million during the quarter, compared to analysts’ expectations of $964.61 million. During the same quarter last year, the firm posted $0.76 earnings per share. Bruker’s revenue for the quarter was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts anticipate that Bruker will post 2.69 EPS for the current year.

Insider Buying and Selling

In other news, VP Mark Munch sold 7,000 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $55.00, for a total value of $385,000.00. Following the transaction, the vice president owned 128,443 shares of the company’s stock, valued at $7,064,365. This represents a 5.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 11,000 shares of company stock valued at $554,280. 27.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Bruker

Institutional investors have recently modified their holdings of the company. Los Angeles Capital Management LLC bought a new position in Bruker during the fourth quarter valued at approximately $26,000. Allworth Financial LP lifted its holdings in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares in the last quarter. Spire Wealth Management boosted its stake in shares of Bruker by 85.3% in the 3rd quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 665 shares in the last quarter. Finally, Summit Securities Group LLC bought a new position in shares of Bruker during the 4th quarter valued at $50,000. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.